Greenwich LifeSciences (Greenwich LifeSciences) Margin of Safety % (DCF FCF Based) : N/A (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Greenwich LifeSciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Greenwich LifeSciences's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Greenwich LifeSciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Greenwich LifeSciences's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Margin of Safety % (DCF FCF Based) falls into.

Greenwich LifeSciences Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477

Website

https://www.greenwichlifesciences.com

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.

Executives

Snehal Patel	director, officer: CHIEF EXECUTIVE OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson	officer: VPC AND REGULATORY AFFAIRS	2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty	director, officer: CHIEF MEDICAL OFFICER	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams	director	2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe	director	2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel	10 percent owner	3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel	10 percent owner	50726 LAKESIDE DRIVE, GRANGER IN 46530